Innocan Pharma’s Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Get inside Wall Avenue with StreetInsider Premium. Declare your 1-week free trial here.

Herzliya, Israel and Calgary Alberta–(Newsfile Corp. – June 11, 2021) – Innocan Pharma Company (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Firm” or “Innocan“), is happy to announce {that a} latest examine carried out on mice demonstrated a protracted launch of cannabidiol (CBD) into the animals’ bloodstream for no less than 7 weeks following native two injections. Innocan believes this end result to be extraordinarily encouraging, given the 24-hour most CBD presence within the bloodstream when administered by means of conventional channels.

This examine was led by Dr. Ahuva Cern, a senior researcher within the lab of Prof. Chezy Berenholz of The Hebrew College of Jerusalem and is predicated on Innocan’s licensed CBD-loaded liposome platform expertise (“LPT“) for injectable CBD options.

“We’re extraordinarily happy with the preliminary outcomes of this examine which exhibits vital enchancment in administrating CBD by means of Innocan’s LPT,” says Professor Chezy Berenholz, “Discovering a remaining CBD within the injection web site, might point out even an extended extended launch of CBD into the bloodstream.”

“This examine marks one other optimistic and thrilling end in our ongoing injectable-CBD analysis,” acknowledged Innocan CEO, Iris Bincovich, who added that, “These outcomes could open the door to a variety of thrilling therapeutic prospects, particularly in remedy of circumstances associated to the central nervous system.”

Innocan’s relationship with The Hebrew College

Innocan Pharma Ltd., an entirely owned subsidiary of the Firm, has entered right into a worldwide unique analysis and license settlement with Yissum Analysis and Growth Firm (“Yissum“), the industrial arm of The Hebrew College of Jerusalem, with respect to the design, preparation, characterization and analysis of hydrogels containing CBD (or different cannabinoids) loaded liposomes. The analysis and improvement initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Analysis Division at The Hebrew College, which is the inventor of over fifty-five patent households, two of which underlie Doxil®, an FDA-approved drug for breast most cancers remedy. This distinctive liposome platform expertise could have a variety of functions, resembling epilepsy, ache reduction, irritation and central nervous system problems. A patent was filed protecting this expertise on October 7, 2019.

About Innocan

Innocan Pharma is a pharmaceutical tech firm that focuses on the event of a number of drug supply platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv College, are collaborating on a brand new, revolutionary exosome-based expertise that targets each central nervous system (CNS) indications and the COVID-19 Corona Virus utilizing CBD. CBD-loaded exosomes maintain the potential to assist in the restoration of contaminated lung cells. This product, which is anticipated to be administered by inhalation, will probably be examined in opposition to quite a lot of lung infections.

Innocan Pharma signed a worldwide unique license settlement with Yissum, the industrial arm of The Hebrew College of Jerusalem, to develop a CBD drug supply platform based mostly on a unique-controlled launch liposome to be administered by injection. Innocan Israel plans, along with Professor Berenholz, to check the liposome platform on a number of potential circumstances. Innocan Israel can be engaged on a dermal product that integrates CBD with different pharmaceutical substances in addition to the event and sale of CBD-integrated prescription drugs, together with, however not restricted to, topical therapies for the reduction of psoriasis signs in addition to the remedy of muscle ache and rheumatic ache. The founders and officers of Innocan Israel every have commercially profitable monitor information within the pharmaceutical and expertise sectors in Israel and globally.

For additional info, please contact:

For Innocan Pharma Company:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

Lytham Companions, LLC
Ben Shamsian CPA | Vice President

Direct: 646-829-9701; Cell: 516-652-9004`Shamsian

shamsian@lythampartners.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Warning concerning forward-looking info

Sure info set forth on this information launch, together with, with out limitation, info concerning analysis and improvement, collaborations, the potential for remedy of circumstances and different therapeutic results ensuing from analysis actions and/or the Firm’s merchandise, requisite regulatory approvals and the timing for market entry, is forward-looking info throughout the that means of relevant securities legal guidelines. the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking info throughout the that means of relevant securities legal guidelines. By its nature, forward-looking info is topic to quite a few dangers and uncertainties, a few of that are past Innocan’s management. The forward-looking info contained on this information launch is predicated on sure key expectations and assumptions made by Innocan, together with expectations and assumptions in regards to the anticipated advantages of the merchandise, satisfaction of regulatory necessities in varied jurisdictions and passable completion of requisite manufacturing and distribution preparations.

Ahead-looking info is topic to varied dangers and uncertainties which might trigger precise outcomes and expertise to vary materially from the anticipated outcomes or expectations expressed on this information launch. The important thing dangers and uncertainties embody however should not restricted to: common world and native (nationwide) financial, market and enterprise circumstances; governmental and regulatory necessities and actions by governmental authorities; and relationships with suppliers, producers, prospects, enterprise companions and opponents. There are additionally dangers which are inherent within the nature of product distribution, together with import / export issues and the failure to acquire any required regulatory and different approvals (or to take action in a well timed method) and availability in every market of product inputs and completed merchandise. The anticipated timeline for entry to markets could change for a lot of causes, together with the lack to safe needed regulatory necessities, or the necessity for extra time to conclude and/or fulfill the manufacturing and distribution preparations. Because of the foregoing, readers shouldn’t place undue reliance on the forward-looking info contained on this information launch in regards to the timing of launch of product distribution. A complete dialogue of different dangers that impression Innocan will also be present in Innocan’s public stories and filings which can be found underneath Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance shouldn’t be positioned on forward-looking info as precise outcomes could fluctuate materially from the forward-looking info. Innocan doesn’t undertake to replace, appropriate or revise any forward-looking info on account of any new info, future occasions or in any other case, besides as could also be required by relevant legislation.

To view the supply model of this press launch, please go to https://www.newsfilecorp.com/release/87240